Where I see patients (3)
Selected research
-
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
Blood
-
Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.
European journal of haematology
-
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Blood
Contact me
Saving future lives
500+ UCSF investigators are researching cures for hundreds of childhood and adult diseases.
